Summary of COVID-19 GB0139 studies
Hide extended summaries
RCT 41 hospitalized COVID-19 pneumonitis patients showing inhaled GB0139, a galectin-3 inhibitor, was well-tolerated with no treatment-related serious adverse events. There were greater rates of decline in inflammatory markers (CRP, LDH, neutrophil-lymphocyte ratio) and coagulation markers in the GB0139 group, but no significant differences in clinical outcomes.
Jan 2023, American J. Respiratory and Critical Care Medicine, https://www.atsjournals.org/doi/10.1164/rccm.202203-0477OC, https://c19p.org/gaughan
1. Gaughan et al., An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE)
41 patient GB0139 late treatment RCT: 40% higher mortality (p=0.7) and 100% longer hospitalization.RCT 41 hospitalized COVID-19 pneumonitis patients showing inhaled GB0139, a galectin-3 inhibitor, was well-tolerated with no treatment-related serious adverse events. There were greater rates of decline in inflammatory markers (CRP, LDH, neutrophil-lymphocyte ratio) and coagulation markers in the GB0139 group, but no significant differences in clinical outcomes.
Jan 2023, American J. Respiratory and Critical Care Medicine, https://www.atsjournals.org/doi/10.1164/rccm.202203-0477OC, https://c19p.org/gaughan
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.